Massachusetts General Hospital researchers and Prevencio announce the power of artificial intelligence HART platform for medical diagnostic test development
Prevencio, Inc. announced the culminative presentation of patient data demonstrating that its Artificial Intelligence (AI)-driven HART blood tests are highly accurate in a broad range of patients, including those suffering from diabetes, chronic kidney disease, hypertension, obesity, coronary heart disease, heart failure, chronic total occlusion (CTO) of the heart arteries, and Kawasaki disease. The HART platform is disease agnostic and may be used to develop diagnostics beyond cardiac disease.
Two of Prevencio’s tests, HART CVE and HART CADhs, are currently available to medical professionals for patient use. HART CVE determines a patient’s one-year risk for a heart attack, stroke, or cardiovascular death, while HART CADhs assesses whether a patient has obstruction of the heart arteries and is at imminent risk of a heart attack.
Researchers from Massachusetts General Hospital (MGH) tested more than 1,250 patients undergoing coronary or peripheral angiography to collaborate in the development and validation of the AI-driven HART platform which has produced seven highly accurate, algorithmic multiple protein blood tests.
